These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36418073)

  • 1. Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response.
    Stirling ER; Terabe M; Wilson AS; Kooshki M; Yamaleyeva LM; Alexander-Miller MA; Zhang W; Miller LD; Triozzi PL; Soto-Pantoja DR
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36418073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment.
    Nath PR; Pal-Nath D; Mandal A; Cam MC; Schwartz AL; Roberts DD
    Cancer Immunol Res; 2019 Sep; 7(9):1547-1561. PubMed ID: 31362997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation.
    Schwartz AL; Nath PR; Allgauer M; Lessey-Morillon EC; Sipes JM; Ridnour LA; Morillon Ii YM; Yu Z; Restifo NP; Roberts DD
    Cancer Immunol Immunother; 2019 Nov; 68(11):1805-1817. PubMed ID: 31628526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy.
    Soto-Pantoja DR; Terabe M; Ghosh A; Ridnour LA; DeGraff WG; Wink DA; Berzofsky JA; Roberts DD
    Cancer Res; 2014 Dec; 74(23):6771-83. PubMed ID: 25297630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CD47 enhanced the antitumor immunity of PD-L1 blockade in B-cell lymphoma.
    Nan Y; Zhang X; Wang S; Xu C; Wang Y; Han L; Luan J; Hu X; Chen W; Cao Z; Zhu Z; Zeng X; Fan J; Ye L; Shi X; Ju D
    Immunotherapy; 2023 Feb; 15(3):175-187. PubMed ID: 36727256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD47 and thrombospondin-1 regulation of mitochondria, metabolism, and diabetes.
    Roberts DD; Isenberg JS
    Am J Physiol Cell Physiol; 2021 Aug; 321(2):C201-C213. PubMed ID: 34106789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombospondin-1, CD47, and SIRPα display cell-specific molecular signatures in human islets and pancreata.
    Erdem N; Chen KT; Qi M; Zhao Y; Wu X; Garcia I; Ku HT; Montero E; Al-Abdullah IH; Kandeel F; Roep BO; Isenberg JS
    Am J Physiol Endocrinol Metab; 2023 Apr; 324(4):E347-E357. PubMed ID: 36791324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
    Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
    Front Immunol; 2022; 13():794684. PubMed ID: 35720386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD47 signaling regulates the immunosuppressive activity of VEGF in T cells.
    Kaur S; Chang T; Singh SP; Lim L; Mannan P; Garfield SH; Pendrak ML; Soto-Pantoja DR; Rosenberg AZ; Jin S; Roberts DD
    J Immunol; 2014 Oct; 193(8):3914-24. PubMed ID: 25200950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.
    Jeanne A; Boulagnon-Rombi C; Devy J; Théret L; Fichel C; Bouland N; Diebold MD; Martiny L; Schneider C; Dedieu S
    Clin Exp Metastasis; 2016 Oct; 33(7):637-49. PubMed ID: 27349907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-associated induction of cell membrane CD47 limits basal and temperature-induced changes in cutaneous blood flow.
    Rogers NM; Roberts DD; Isenberg JS
    Ann Surg; 2013 Jul; 258(1):184-91. PubMed ID: 23275312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting HDAC6 improves anti-CD47 immunotherapy.
    Gracia-Hernandez M; Yende AS; Gajendran N; Alahmadi Z; Li X; Munoz Z; Tan K; Noonepalle S; Shibata M; Villagra A
    J Exp Clin Cancer Res; 2024 Feb; 43(1):60. PubMed ID: 38414061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation.
    Miller TW; Kaur S; Ivins-O'Keefe K; Roberts DD
    Matrix Biol; 2013 Aug; 32(6):316-24. PubMed ID: 23499828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD47 Activation by Thrombospondin-1 in Lymphatic Endothelial Cells Suppresses Lymphangiogenesis and Promotes Atherosclerosis.
    Singla B; Aithbathula RV; Pervaiz N; Kathuria I; Swanson M; Ekuban FA; Ahn W; Park F; Gyamfi M; Cherian-Shaw M; Singh UP; Kumar S
    Arterioscler Thromb Vasc Biol; 2023 Jul; 43(7):1234-1250. PubMed ID: 37259865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular TSP1-CD47 signaling promotes sickle cell-associated arterial vasculopathy and pulmonary hypertension in mice.
    Novelli EM; Little-Ihrig L; Knupp HE; Rogers NM; Yao M; Baust JJ; Meijles D; St Croix CM; Ross MA; Pagano PJ; DeVallance ER; Miles G; Potoka KP; Isenberg JS; Gladwin MT
    Am J Physiol Lung Cell Mol Physiol; 2019 Jun; 316(6):L1150-L1164. PubMed ID: 30892078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TSP1-CD47 signaling is upregulated in clinical pulmonary hypertension and contributes to pulmonary arterial vasculopathy and dysfunction.
    Rogers NM; Sharifi-Sanjani M; Yao M; Ghimire K; Bienes-Martinez R; Mutchler SM; Knupp HE; Baust J; Novelli EM; Ross M; St Croix C; Kutten JC; Czajka CA; Sembrat JC; Rojas M; Labrousse-Arias D; Bachman TN; Vanderpool RR; Zuckerbraun BS; Champion HC; Mora AL; Straub AC; Bilonick RA; Calzada MJ; Isenberg JS
    Cardiovasc Res; 2017 Jan; 113(1):15-29. PubMed ID: 27742621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.